CONMED (CNMD)
(Delayed Data from NYSE)
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD), owing to its broad product spectrum.
CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales
by Zacks Equity Research
CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.
Conmed (CNMD) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of -54.84% and 18.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Earnings to Watch on Feb 2: BDX, DGX & CNMD
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how BDX, DGX and CNMD are likely to fare this time.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Why Is Conmed (CNMD) Up 6.8% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MMSI vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MMSI vs. CNMD: Which Stock Is the Better Value Option?
CONMED (CNMD) Down on In-Line Q3 Earnings & Lower 2022 View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings reflect strong segmental performance. Unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin.
Conmed (CNMD) Beats Q3 Earnings Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 2.67% and 2.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate LabCorp (LH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Conmed (CNMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons to Retain CONMED (CNMD) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
PDCO vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
CONMED (CNMD) Acquires Soft Tissue Implant Start-Up Biorez
by Zacks Equity Research
CONMED (CNMD) acquires privately-held Biorez, Inc. for $85 million. The deal is set to boost CONMED's sports medicine portfolio with the addition of Biorez's proprietary BioBrace Implant technology.
PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
CONMED (CNMD) Down on In-Line Q2 Earnings & Lower 2022 View
by Zacks Equity Research
CONMED's (CNMD) adjusted second-quarter earnings reflect strong segmental performance. However, unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin.
Conmed (CNMD) Q2 Earnings Meet Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 0% and 1.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
PDCO or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
Conmed (CNMD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to gain momentum from a solid product portfolio and a strong General Surgery business. However, data security issues linger.
PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
New Strong Sell Stocks for June 30th
by Zacks Equity Research
WMT, EC, and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2022.
Patterson Cos. (PDCO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of 26.79% and 1.71%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for June 27th
by Zacks Equity Research
CNMD, WMT, and CAH have been added to the Zacks Rank #5 (Strong Sell) List on June 27, 2022.
CONMED (CNMD) to Expand Orthopedic Portfolio With Buyout
by Zacks Equity Research
CONMED's (CNMD) completion of In2Bones Global buyout will expand its orthopedic portfolio.